Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy

Familial Cancer

Volumn 11, Issue 1, 2012, Pages 41-47

  Ghiorzo, P ^a   Pensotti, V ^b   Fornarini, G ^c   Sciallero, S ^c   Battistuzzi, L ^a   Belli, F ^d   Bonelli, L ^e   Borgonovo, G ^a   Bruno, W ^a   Gozza, A ^d   Gargiulo, S ^a   Mastracci, L ^a   Nasti, S ^a   Palmieri, G ^f   Papadia, F ^a   Pastorino, L ^a   Russo, A ^g   Savarino, V ^h   Varesco, L ^c   Bernard, L ⁱ   Bianchi Scarra G ^a,c   more..

^a UNIVERSITY OF GENOA   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f CNR   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

BRCA; Germline mutation; Hereditary breast ovarian cancer syndrome (HBOC); PALB2; Pancreatic cancer susceptibility

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NUCLEAR PROTEIN; PALB2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE DELETION; GENE MUTATION; GERM LINE; HUMAN; MALE; MEDICAL HISTORY; MUTATION RATE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; ITALY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PEDIGREE; TUMOR SUPPRESSOR PROTEINS;

EID: 84858293392     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-011-9483-5     Document Type: Article

References (31)

1. Easton D, Thompson D, McGuffog L, Haites N, Schofield A, Scott RJ, King M-C, Schubert E, Bignon Y, Stratton M, Ford D, Peto J, Eeles R, Ponder B, Gayther S, Chang-Claude J, Weber BHF, Hamann U, Benitez J, Osorio A, Eerola H, Nevanlinna H, Lynch HT, Narod S, Goldgar D, Lenoir G, Stoppa-Lyonnet D, Arason A, Barkardottir R, Egilsson V, Eyfjord J, Tulinius H, Bishop DT, Borg A, Loman N, Johannsson O, Olsson H, Tonin P, Foulkes W, Ghadirian P, Mes-Masson AM, Provencher D, Weber B, Devilee P, Vasen H, Cornelisse CJ, Meijers-Heijboer H, Klijn JGM, Narod S, Brunet J-S, Moslehi R, Neuhausen S, Cannon- Albright L (1999) Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310-1316 (Pubitemid 29387573)
2. Lal G, Liu G, Schmocker B et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germline p16, BRCA1 and BRCA2 mutations. Cancer Res 60:409-416 (Pubitemid 30070770)
3. Thompson D, Easton DF et al (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365 (Pubitemid 35154140)
4. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42:711-719 (Pubitemid 41306062)
5. Lynch HT, Deters CA, Snyder CL et al (2005) BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 158:119-125 (Pubitemid 40417693)
6. Greer JB, Whitcomb DC (2007) Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut 56:601-605 (Pubitemid 46662919)
7. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, Canto MI (2007) Participants of the fourth international symposium of inherited diseases of the pancreas. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460-1469
8. Lawniczak M, Gawin A, Białek A, Lubiński J, Starzyńska T (2008) Is there any relationship between BRCA1 gene mutation and pancreatic cancer development? Pol Arch Med Wewn 118:645-649
9. Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME (2009) BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 27:433-438
10. Al-Sukhni W, Rothenmund H, Borgida AE, Zogopoulos G, O'Shea AM, Pollett A, Gallinger S (2008) Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet 124:271-278
11. Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME (2011) Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. doi:10.1002/cncr.26191
12. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719-729
13. Tischkowitz M, Xia B (2010) PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 70:7353-7359
14. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217
15. Stadler ZK, Salo-Mullen E, Sabbaghian N, Simon JA, Zhang L, Olson SH, Kurtz R, Offit K, Foulkes WD, Robson ME, Tischkowitz M (2011) Germline PALB2 mutation analysis in breast-pancreas cancer families. J Med Genet 48:523-525
16. Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivastava A, Holter S, Rothenmund H, Ghadirian P, Foulkes WD, Gallinger S (2009) Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137:1183-1186
17. Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N (2011) PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 10:225-231
18. Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC (2011) Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res Mar 1571:2222-2229
19. Peterlongo P, Catucci I, Pasquini G, Verderio P, Peissel B, Barile M, Varesco L, Riboni M, Fortuzzi S, Manoukian S, Radice P (2011) PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. Breast Cancer Res Treat 126:825-828
20. Adank MA, van Mil SE, Gille JJ, Waisfisz Q, Meijers-Heijboer H (2011) PALB2 analysis in BRCA2-like families. Breast Cancer Res Treat 127:357-362
21. Ghiorzo P, Pastorino L, Bonelli L, Cusano R, Nicora A, Zupo S, Queirolo P, Sertoli M, Pugliese V, Bianchi-Scarrà G (2004) INK4/ARF germline alterations in pancreatic cancer patients. Ann Oncol 15:70-78 (Pubitemid 38139606)
22. Ghiorzo P, Gargiulo S, Nasti S, Pastorino L, Battistuzzi L, Bruno W, Bonelli L, Taveggia P, Pugliese V, Borgonovo G, Mastracci L, Fornarini G, Romagnoli P, Iiritano E, Savarino V, Bianchi-Scarrà G (2007) Predicting the risk of pancreatic cancer: on CDKN2A mutations in the melanoma-pancreatic cancer syndrome in Italy. J Clin Oncol 25:5336-5337 (Pubitemid 350232278)
23. Gargiulo S, Torrini M, Ollila S, Nasti S, Pastorino L, Cusano R, Bonelli L, Battistuzzi L, Mastracci L, Bruno W, Savarino V, Sciallero S, Borgonovo G, Nyström M, Bianchi-Scarrà G, Mareni C, Ghiorzo P (2009) Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Fam Cancer 8:547-553
24. Sluiter M, Mew S, van Rensburg EJ (2009) PALB2 sequence variants in young South African breast cancer patients. Fam Cancer 8:347-353
25. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP (2010) Update on familial pancreatic cancer. Adv Surg 44:293-311 Review
26. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian V.I.2011. Available at http://www.NCCN.com
27. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A (2005) BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 4:934-936 (Pubitemid 41598586)
28. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB (2010) Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. J Clin Oncol 28(15):2512-2519
29. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244
30. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL (2011) Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 31:1417-1420
31. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ (2011) Therapeutic potential of poly(-ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103:334-346